| Date Filed | Type | Description |
| 05/25/2023 |
4
| ROSA-BJORKESON DAGMAR (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,111 shares
@ $0
Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
| 06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/25/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/05/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/04/2019 |
4
| ROSA-BJORKESON DAGMAR (Chief Strat & Corp Dev Officer) has filed a Form 4 on Mallinckrodt plc|
Txns:
| Paid exercise price by delivering 246 shares
@ $9.06, valued at
$2.2k
|
|
| 04/05/2019 |
4/A
| ROSA-BJORKESON DAGMAR (Chief Strat & Corp Dev Officer) has filed a Form 4 on Mallinckrodt plc|
Txns:
| Granted 34,953 options to buy
@ $0 |
|
| 04/03/2019 |
4
| ROSA-BJORKESON DAGMAR (Chief Strat & Corp Dev Officer) has filed a Form 4 on Mallinckrodt plc|
Txns:
| Granted 7,638 shares
@ $0
Paid exercise price by delivering 1,063 shares
@ $22.8, valued at
$24.2k
Granted 34,953 options to buy
@ $22.62, valued at
$790.6k
|
|
| 06/05/2018 |
4
| ROSA-BJORKESON DAGMAR (Chief Strat & Corp Dev Officer) has filed a Form 4 on Mallinckrodt plc|
Txns:
| Paid exercise price by delivering 247 shares
@ $17.05, valued at
$4.2k
|
|
| 04/30/2018 |
3
| ROSA-BJORKESON DAGMAR (Chief Strat & Corp Dev Officer) has filed a Form 3 on Mallinckrodt plc |
| 06/07/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/07/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |